TITLE

Radiotherapy quality assurance review in a multi-center randomized trial of limited-disease small cell lung cancer: the Japan Clinical Oncology Group (JCOG) trial 0202

AUTHOR(S)
Sanuki-Fujimoto, Naoko; Ishikura, Satoshi; Hayakawa, Kazushige; Kubota, Kaoru; Nishiwaki, Yutaka; Tamura, Tomohide
PUB. DATE
January 2009
SOURCE
Radiation Oncology;2009, Vol. 4, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The purpose of this study was to analyze the radiotherapy (RT) quality assurance (QA) assessment in Japan Clinical Oncology Group (JCOG) 0202, which was the first trial that required on-going RT QA review in the JCOG. Methods: JCOG 0202 was a multi-center phase III trial comparing two types of consolidation chemotherapy after concurrent chemoradiotherapy for limited-disease small cell lung cancer. RT requirements included a total dose of 45 Gy/30 fx (bis in die, BID/twice a day) without heterogeneity correction; elective nodal irradiation (ENI) of 30 Gy; at least 1 cm margin around the clinical target volume (CTV); and interfraction interval of 6 hours or longer. Dose constraints were defined in regards to the spinal cord and the lung. The QA assessment was classed as per protocol (PP), deviation acceptable (DA), violation unacceptable (VU), and incomplete/not evaluable (I/NE). Results: A total of 283 cases were accrued, of which 204 were fully evaluable, excluding 79 I/NE cases. There were 18 VU in gross tumor volume (GTV) coverage (8% of 238 evaluated); 4 VU and 23 DA in elective nodal irradiation (ENI) (2% and 9% of 243 evaluated, respectively). Some VU were observed in organs at risk (1 VU in the lung and 5 VU in the spinal cord). Overall RT compliance (PP + DA) was 92% (187 of 204 fully evaluable). Comparison between the former and latter halves of the accrued cases revealed that the number of VU and DA had decreased. Conclusion: The results of the RT QA assessment in JCOG 0202 seemed to be acceptable, providing reliable results.
ACCESSION #
42095030

 

Related Articles

  • How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question. Fojo, Tito; Grady, Christine // JNCI: Journal of the National Cancer Institute;8/5/2009, Vol. 101 Issue 15, p1044 

    The spiraling cost of cancer care, in particular the cost of cancer therapeutics that achieve only marginal benefits, is under increasing scrutiny. Although health-care professionals avoid putting a value on a life, our limited resources require that society address what counts as a benefit, the...

  • Lack of initial response to chemoradiotherapy linked to poorer outcome.  // Hem/Onc Today;9/10/2012, Vol. 13 Issue 17, p39 

    The article discusses research which reveals that patients with small cell lung cancer who failed to achieve complete/partial response following their first course of platin-based chemoradiotherapy suffered a poorer outcome, despite getting an objective response throughout the treatment course.

  • Outcomes research in cancer clinical trial cooperative groups: the RTOG model. Bruner, D. W.; Movsas, B.; Konski, A.; Roach, M.; Bondy, M.; Scarintino, C.; Scott, C.; Curran, W. // Quality of Life Research;Aug2004, Vol. 13 Issue 6, p1025 

    Background: The Radiation Therapy Oncology Group (RTOG), a National Cancer Institute sponsored cancer clinical trials research cooperative, has recently formed an Outcomes Committee to assess a comprehensive array of clinical trial endpoints and factors impacting the net effect of...

  • Restrictive Eligibility Limits Access to Newer Therapies in Non–Small-Cell Lung Cancer: The Implications of Eastern Cooperative Oncology Group 4599. Somer, Robert A.; Sherman, Eric; Langer, Corey J. // Clinical Cancer Update;Dec2008, Vol. 2 Issue 1, p54 

    BACKGROUND: In a previous randomized phase II trial evaluating carboplatin and paclitaxel with or without bevacizumab in patients naive to chemotherapy with advanced non–small-cell lung cancer (NSCLC), median survival ranged from 53 weeks to 76 weeks. Sudden life-threatening hemoptysis...

  • Radiothérapie des cancers bronchiques non à petites cellules. Progrès actuels. Modalités futures. Girard, N.; Belliere, A.; Mornex, F. // Oncologie;jan2006, Vol. 8 Issue 1, p29 

    Radiotherapy is a major treatment in thoracic oncology: whereas surgery is the treatment of early stage lung tumours, and chemotherapy is used in a neo-adjuvant, adjuvant setting, and in metastatic patients, concurrent chemoradiation is the standard treatment of unresectable locally advanced...

  • Stereotactic Body Radiation Therapy: Approaches in Early-Stage NSCLC. Nichols, Emma Hitt // MD Conference Express;Jun2014, Vol. 14 Issue 3, p17 

    Stereotactic body radiation therapy (SBRT) is effective in patients with early-stage non—small cell lung cancer (NSCLC) who are either medically inoperable or high-risk operable. This article discusses treatment approaches and considerations for the use of SBRT in this population.

  • Identical chemotherapy schedules given on and off trial protocol in small cell lung cancer response and survival results. Burgers, J.A.; Arance, A.; Ashcroft, L.; Hodgetts, J.; Lomax, L.; Thatcher, N. // British Journal of Cancer;8/27/2002, Vol. 87 Issue 5, p562 

    Patients who are treated within clinical trials may have a survival benefit dependent on being a trial participant. A number of factors may produce such beneficial outcome including more rigorous adherence to a peer reviewed trial protocol, management by an experienced treatment team, being...

  • Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. Baka, S.; Califano, R.; Ferraldeschi, R.; Aschroft, L.; Thatcher, N.; Taylor, P.; Faivre-Finn, C.; Blackhall, F.; Lorigan, P. // British Journal of Cancer;8/5/2008, Vol. 99 Issue 3, p442 

    This randomised trial compared platinum-based to anthracycline-based chemotherapy in patients with small-cell lung cancer (limited or extensive stage) and 2 adverse prognostic factors. Patients were randomised to receive six cycles of either ACE (doxorubicin 50 mg/m2 i.v.,...

  • Current and emerging therapies for patients with advanced non-small-cell lung cancer. SHETH, SHEETAL // American Journal of Health-System Pharmacy;1/1/2010 Supplement, Vol. 67 Issue S1, pS9 

    Purpose. To review recent clinical trials that have examined new options for the treatment of non-small-cell lung cancer (NSCLC) and to review the importance of tumor histology and genetics in the selection of therapy. Summary. Targeted biological agents have been evaluated for use in patients...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics